Loss of ovarian function in the VCD mouse-model of menopause leads to insulin resistance and a rapid progression into the metabolic syndrome.
Factors comprising the metabolic syndrome occur with increased incidence in postmenopausal women. To investigate the effects of ovarian failure on the progression of the metabolic syndrome, female B(6)C(3)F(1) mice were treated with 4-vinylcyclohexene diepoxide (VCD) and fed a high-fat (HF) diet for 16 wk. VCD destroys preantral follicles, causing early ovarian failure and is a well-characterized model for the gradual onset of menopause. After 12 wk on a HF diet, VCD-treated mice had developed an impaired glucose tolerance, whereas cycling controls were unaffected [12 wk AUC HF mice 13,455 +/- 643 vs. HF/VCD 17,378 +/- 1140 mg/dl/min, P < 0.05]. After 16 wk on a HF diet, VCD-treated mice had significantly higher fasting insulin levels (HF 5.4 +/- 1.3 vs. HF/VCD 10.1 +/- 1.4 ng/ml, P < 0.05) and were significantly more insulin resistant (HOMA-IR) than cycling controls on a HF diet (HF 56.2 +/- 16.7 vs. HF/VCD 113.1 +/- 19.6 mg/dl x microU/ml, P < 0.05). All mice on a HF diet gained more weight than mice on a standard diet, and weight gain in HF/VCD mice was significantly increased compared with HF cycling controls. Interestingly, even without a HF diet, progression into VCD-induced menopause caused a significant increase in cholesterol and free fatty acids. Furthermore, in mice fed a standard diet (6% fat), insulin resistance developed 4 mo after VCD-induced ovarian failure. Insulin resistance following ovarian failure (menopause) was prevented by estrogen replacement. Studies here demonstrate that ovarian failure (menopause) accelerates progression into the metabolic syndrome and that estrogen replacement prevents the onset of insulin resistance in VCD-treated mice. Thus, the VCD model of menopause provides a physiologically relevant means of studying how sex hormones influence the progression of the metabolic syndrome.
Romero-Aleshire
Melissa J
MJ
Dept. of Physiology, College of Medicine, 1656 E Mabel St, Univ. of Arizona, Tucson, AZ 85724-5218, USA.
Diamond-Stanic
Maggie K
MK
Hasty
Alyssa H
AH
Hoyer
Patricia B
PB
Brooks
Heddwen L
HL
D050153:Abdominal Fat / Q000503:physiopathology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D053138:Cyclohexenes; D004041:Dietary Fats; D004195:Disease Models, Animal; D018450:Disease Progression; D015914:Estrogen Replacement Therapy; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008593:Menopause; D024821:Metabolic Syndrome / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D051379:Mice; D010053:Ovary / Q000503:physiopathology*; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced / Q000150:complications / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D013997:Time Factors; D014753:Vinyl Compounds; D015430:Weight Gain
D001786:Blood Glucose; D053138:Cyclohexenes; D004041:Dietary Fats; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D014753:Vinyl Compounds; C012606:4-vinyl-1-cyclohexene dioxide; D002784:Cholesterol